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Pinnaclea b s t r a c t
Background: Treatment plans for head and neck (H&N) cancer are highly complex due to multiple dose
prescription levels and numerous organs at risk (OARs) close to the target. The plan quality is inter-
planner dependent since it is dependent on the skills and experience of the dosimetrist. This study
presents a blinded prospective clinical comparison of automatic (AU) and manually (MA) generated
H&N VMAT plans made for clinical use.
Methods: MA and AU plans were generated for 30 consecutive patients in Pinnacle3 using the IMRT opti-
misation module and the new Autoplan module, respectively. The plan quality was blindedly compared
by three senior oncologists and the best plan was selected for treatment of the patient. Planning time was
measured as the active operator time used. The plan quality was analysed with DVH metrics and the dose
delivery accuracy validated on the ArcCheck phantom.
Results: For twenty-nine out of the thirty patients the AU plan was chosen for treatment. Target doses
were more homogenous with the AU plans and the OAR doses were significantly reduced, between 0.5
and 6.5 Gy. The average operator time spent on creating a manual plan was 64 min which was halved
by Autoplan. The AU plans were more modulated as illustrated by an increase in MUs, which might cause
the slightly lower pass rate of 97.7% in the ArcCheck measurements.
Conclusions: Target doses were similar between MA and AU plan, while AU plans spared all OAR consid-
erably better than the MA plans.
 2016 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Radiotherapy of head and neck (H&N) cancer is challenging due
to complex shaped targets situated close to numerous radiosensi-
tive organs at risk (OARs). Thus, a high quality H&N plan is con-
form, has homogeneous target doses according to prescription
and as low doses to OAR’s as possible with a proper balance
between target coverage and OAR doses. The plan quality has been
shown to directly affect treatment outcome in clinical trials, which
in itself has created a new era of quality assurance [1,2].
Obtaining high quality plans is a demanding task. A high quality
treatment plan relies on the skills and experience of the dosime-
trist, which can vary greatly. Even for the most experienceddosimetrist, time pressure to deliver a clinically applicable dose
plan may result in treatment plans of inferior quality than desired.
With several OARs in play in the head and neck region, there may
be a tendency to focus more on specific OARs and thereby disre-
garding the importance of other risk organs during the optimisa-
tion process. This results in plans with acceptable target coverage
and adequate sparing of e.g. the spinal cord and parotids, but for
which e.g. the oral cavity and constrictor muscles are irradiated
to higher levels than necessary [3]. This is not necessarily due to
lack of skills or experience of the dosimetrist, but merely due to
the ability to focus on only a limited number of objectives at a
time.
The user-dependant variation of plan quality can be improved
by applying specific guidelines which define the minimum stan-
dards for dose targets and OARs [4]. Such guidelines can to some
extent reduce the overall variation of the dosimetrist-dependant












Oral cavity 3 10
Pharynx 15 50
Larynx 4 13
Salivary glands 2 7
Thyroid gland 2 7






Squamous cell 27 90
Adenocarcinoma 1 3
Papillary carcinoma 1 3
Invasive ductal carcinoma 1 3
HPV status (p16 expression)
Positive 12 40
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acceptable level.
Recently, new techniques have been applied for head and neck
treatments such as Volume modulated arc therapy (VMAT) [5],
Tomotherapy [6] and proton therapy [7]. These technical develop-
ments have increased the degrees of freedom compared to inten-
sity modulated radiotherapy (IMRT) and thereby made it possible
to improve the plan quality. Various approaches have been made
for an automatic search for the optimal patient plan such as
atlas-based planning (RapidPlan [8]), ideal dose distribution esti-
mation (PlanIQ [9] and Erasmus-iCycle [10]), and template-based
optimisation as used in AutoPlanning (AP) provided by Pinnacle3
[11,12].
In a previous study, we retrospectively evaluated a research
version of Autoplan in seven field step and shoot IMRT (ssIMRT)
plans for H&N treatment. The results were promising based on
DVH analysis as well as within a blinded clinical plan evaluation
[12]. Since the study was made as a retrospective study, the plans
delivery were not dosimetrically validated, and the plans were
ssIMRT and not VMAT which is the current clinical standard in
our department.
This prospective study presents a blinded comparison study of
automatic and manually generated H&N VMAT plans made for
clinical use utilizing the clinically released version of Autoplan.
Finally, the dosimetric accuracy and deliverability of the generated














* As radiosensitiser, 1.2 g/m2 Nimorazol was administrated before every fraction.
# Cisplatin 40 mg/m2 weekly was used as systemic treatment.
Table 2
Autoplan setup template.
Organs at risk Objective Dose level Compromise
Brain stem Max dose 54 Gy No
Brain stem PRV Max dose 60 Gy No
Spinal cord Max dose 45 Gy No
Spinal cord PRV Max dose 50 Gy No
Parotid gland Mean dose 20 Gy Yes
Submandibular gland Mean dose 35 Gy Yes
Mandible Max dose 107% Yes
Lips Mean dose 20 Gy Yes
Thyroid gland Mean dose 40 Gy Yes
Oral cavity Mean dose 30 Gy Yes
Larynx Mean dose 44 Gy Yes
Constrictor muscles Mean dose 45 Gy Yes
Whole brain Max dose 60 Gy Yes
Autoplan setup for all 30 patients. All values are adopted directly from the
DAHANCA 2013 guidelines. The prioritisation was set automatically for all objec-
tives as described in the text.2. Material and methods
All patients (n = 30) referred to curative H&N radiotherapy in
August and September 2015 were included prospectively. The
demographics (Table 1) are representative for the general entry
of head and neck patients in the cancer centre, though with slightly
more unknown primary tumours and less oral cavity tumours. No
patients were censored from the study.
All patients followed the standard process of radiotherapy plan-
ning, i.e.: immobilisation, CT simulation (slice thickness of 3 mm
and in plane voxel size of 1 mm  1 mm), contouring by a radiolo-
gist and oncologist before the dosimetrist created a MA VMAT plan
and an AU VMAT plan. Treatment planning was performed in
accordance with the Danish Head and Neck Cancer Group’s guide-
lines (DAHANCA – Version 2013 ver. 2.0 [13]) and each dose plan
included up to three dose levels of 66 or 68 Gy (PTV1), 60 Gy
(PTV2) and 50 Gy (PTV3) in 33 or 34 fractions. All plans used the
simultaneous integrated boost technique and a full 360 degree
VMAT arc for bilateral targets and a 200–220 degree VMAT arc
for unilateral targets.
The MA plans were optimised according to standard clinical
practice, with a script template for optimisation objectives. Manual
adjustment of the template predefined objective values were per-
formed a minimum of 3 times guided by the patient-specific pos-
sibilities as determined by the dosimetrist.
The AU plans were created by the Autoplan software available
in Pinnacle3 version 9.10, using settings shown in Table 2. The
spinal cord and brain stem had higher priority than the target cov-
erage (non-compromise); and the remaining OARs were automat-
ically prioritised according to the proportion of overlap with the
target (high if <25% overlap, medium if 25–50% overlap and low
if >50% overlap). After AU optimisation, a minor manual fine-
tuning of the plans was performed for all plans. No direct compar-
isons between the two plans were performed before both plans
were finalised, however the bias of the same dosimetrist making
both plans was minimised by one half of patients having the MA
plans created first and for the other half of the patients having
the AU plan was created first. Dose calculation was performed withthe Pinnacle3 collapsed cone algorithm with a dose grid resolution
of 3 mm and a control point spacing of 2 degrees.
The planning techniques were blinded before MA and AU plans
were presented at the daily clinical radiotherapy conference.




Mean STD Mean STD
CTV1
Mean 100.8 0.3 100.2 0.4 <0.001
D2 103.2 0.7 103.2 1.4 <0.001
D98 97.5 1.9 96.7 1.9 <0.001
PTV1 (66 or 68 Gy)
Mean 100.3 0.3 99.7 0.5 <0.001
D2 103.3 0.6 103.5 1.2 <0.001
D98 96.1 0.9 95.4 0.4 <0.001
CI 1.30 0.14 1.31 0.20 0.52
HI 0.14 0.19 0.15 0.19 0.009
PTV2only (60 Gy)
Mean 103.3 1.0 103.1 1.5 0.16
D2 109.0 1.4 111.8 2.5 0.02
D98 96.9 2.0 95.2 1.6 0.02
CI* 1.85 1.82 1.84 1.78 0.70
HI 0.12 0.03 0.16 0.03 <0.001
PTV3only (50 Gy)
Mean 103.7 2.4 103.0 2.9 0.005
D2 116.8 5.0 120.3 5.7 0.005
D98 98.6 5.1 96.4 5.6 <0.001
CI* 1.71 0.72 1.74 0.72 0.01
HI 0.23 0.16 0.28 0.14 <0.001
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from the DAHANCA guidelines. Plan selection was performed by
three senior H&N oncologists and overviewed by oncologists of
other treatment sites, medical physicists and RTT’s.
To supplement the clinical evaluation, the operator time for the
dosimetrist was recorded, and delivery accuracy of the plans was
validated on an ArcCheck phantom using the pass rate of a gamma
evaluation (3% of max measured dose, 3 mm).
Quantitative dosimetric evaluation of the treatment plans was
performed on Dose Volume Histograms (DVHs) extracted from
the planning system. The average DVH was calculated for each
type of treatment plan as the average of the patient-specific DVH
values at each dose level. The DVH analysis was performed for all
target volumes as well as for the parotid glands, submandibular
glands, the mandible, oral cavity, lips, larynx, thyroid, brain stem,
and spinal cord. To evaluate radiation dose to the remaining
healthy tissue, a DVH evaluation of all healthy tissues was
performed. In contrast to the previous DVH evaluations, this eval-
uation was performed in absolute volume to compensate for a dif-
ference of the CT scanned volume of each patient (relative values
would depend on the scanned volume).
The mean OAR doses and target conformity index (CI = V95%/
VPTV) and homogeneity index (HI = D2%  D98%/Dprescription) were
calculated.All doses are normalised to prescription dose (68, 66, 60 or 50 Gy).
* Conformity index calculated from the full PTV.
Table 4
Organ at risk mean doses.
OAR Unit Autoplan Manual p
Mean STD Mean STD2.1. Statistics
Differences were tested using Wilcoxon matched-pair signed-
rank with a significance level of 5%. To indicate dose regions in
the DVHs for which statistically significant differences exist, a
Wilcoxon matched-pair sign rank probability curve was calculated
as in Bertelsen et al. [5].Spinal cord (Gy) 20.2 6.9 22.9 5.8 <0.001
Brainstem (Gy) 3.5 4.0 5.1 4.7 <0.001
Oral cavity (Gy) 31.6 13.3 34.3 12.8 <0.001
Libs of mouth (Gy) 12.3 7.7 15.2 6.8 <0.001
Parotid gland ipsi* (Gy) 23.4 16.4 25.5 15.7 <0.001
Parotid gland con** (Gy) 18.5 8.1 20.5 8.8 0.004
Submandibular gland ipsi* (Gy) 53.2 11.4 56.0 7.7 0.01
Submandibular gland con** (Gy) 34.0 19.2 40.5 18.9 <0.001
Mandible (Gy) 30.2 9.4 32.3 8.9 <0.001
Thyroid gland (Gy) 34.6 13.3 37.1 11.2 <0.001
Larynx (Gy) 39.1 9.4 44.8 8.7 <0.001
Body (Gy) 9.3 3.0 9.8 2.9 <0.001
Mean doses of the patient specific mean OAR doses. AU reduced the OAR mean
doses for all organs including the whole scanned part of the patient (Body).
* Ipsilateral gland.
** Contralateral gland.3. Results
In 29 of the 30 plans, the AU plan was chosen for clinical appli-
cation (p < 0.001).
All plans adhered to the critical objectives for targets and criti-
cal OAR (spinal cord and brain stem).
In terms of target coverage, the AU plans had a higher mean
dose to all three PTVs. However, the D2 was lower for the AU plans.
The HIs showed that each dose plateau was more homogenous for
the AU plans compared to MA for each individual area of dose pre-
scription. CI of the AU plans was significantly better for PTV3
(Table 3). According to ICRU83 [14], the PTV3 includes PTV2 caus-
ing the long tail towards high doses – likewise, PTV2 contains
PTV1, however analysing PTV2only (PTV2–PTV1) and PTV3only
(PTV3–PTV2), these overdose-tails were significantly reduced by
AU compared to MA.
Mean OAR doses were significantly reduced in the AU plans for
all risk organs. The mean reduction ranged from 0.5 Gy for the
entire patient (body) to 6.5 Gy for the contralateral submandibular
gland (Table 4). Differences in mean DVH showed significant AU
superiority in the dose range 10–45 Gy for all organs. Average
DVH are shown in Fig. 1 for six of the OAR and in Fig. 2 for four ring
structures surrounding the targets. During the clinical plan evalu-
ation, the general impression was that the AU plan was visually
more conform, spared OAR better and had steeper dose fall away
from the targets. The irradiation of OARs was in particular reduced
for the submandibular glands. In Fig. 3 a screen dump of a repre-
sentative patient is shown. Here the sparing of the right sub-
mandibular gland, the extended oral cavity and the spinal cord is
mainly seen for the dose spillage iso-dose curves of 40 and 30 Gy.
The only manual plan selected for clinical use was a non-typical
H&N case for a thyroid cancer involving level VII lymph nodes. Thatis, the plan included a relatively large volume of lung tissue, which
was irradiated to a lesser degree by the manually created plan.
Compared to the MA plans, a larger degree of MLC modulation
was observed for the AU plans which are reflected in an increased
number of monitor units in the AU plans. The pass rate was 97.7%
in AU plans compared with 98.4% for MA plans assessed by
ArcCheck measurements (Table 5). The average beam-on time of
was 4 s longer in the AU plans. Mean operator time spent on MA
plans was more than twice that of AU plans.
Three of the 30 patients had critical OAR adjacent to the PTV1
(high dose target) which required more operator time for both
the MA and AU plans resulting in a relatively large variation in
operator time.4. Discussion
In 29 of the 30 patients the AU plan was selected. In most cases,
the plan selection was straightforward with the AU plans clearly
Fig. 1. Mean DVH of six OAR for all 30 patients. Red line is MA plan and blue line is AU plan. The grey p-value curve illustrates dose regions from around 10 to 45 Gy where AU
plans significantly spare the organs more. The mean dose reductions for these six organs are between 2 to 5 Gy. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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Fig. 2. Mean DVH of four ring-ROI’s for all 30 patients. Black line is MA plan and dotted line is AU plan. Red line is MA plan and blue line is AU plan. The grey p-value curve
illustrates where the AU and MA plans are significantly different.
Fig. 3. Screen dump comparison of a representative patient. Iso-dose curves are 105% (green), 100% (blue) and 95% (yellow) for the three dose prescriptions (68 Gy, 60 Gy and
50 Gy). Dose spillage iso-dose curve are 40 and 30 Gy. The GTV tumour and GTV lymph node are shown in red and orange. CTV1 is shown in light orange, with corresponding
PTV1 in colourwash purple. Colourwash blue and light blue represent PTV2 and PTV3. The contour of the extended oral cavity is brown. The right submandibular gland and
spinal cord are shown in green and the PRV spinal cord in light brown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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Table 5
Treatment delivery metrics.
Target Unit Autoplan Manual p
Mean STD Mean STD
MU MU 435 79 360 56 <0.001
Operator time min 32 26 64 31 <0.001
Beam on time s 114 22 110 24 0.017
Pass rate (3%,3 mm) % 97.7 1.7 98.4 1.7 0.001
Pass rate (2%,2 mm) % 90.6 4.3 92.5 4.5 0.003
Treatment delivery metrics when measured on an ArcCheck phantom.
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few cases the mean OAR doses were similar, with the AU plans only
slightly lower. The only manual plan selected for clinical use was a
non-standard H&N cancer involving level VI and thus including a
large part of the lung. This indicates that the AU plan is more
appropriate for well-established protocols and that special cases
might require several runs with AU to obtain proper setting.
Previously, a research version of Autoplan has been tested in a
retrospective study creating AU ssIMRT plans for 26 H&N patients
[12]. That study investigated the potential of an Autoplan work-
flow and thus did not allow for a manual post optimisation of
the AU plans. Similar to the current study, the AU plans improved
the sparing of the OAR and had target coverage similar to the man-
ual plans. However, due to the decision of no post optimisation of
the AU, ssIMRT plans had slightly reduced target coverage relative
to the manual plans. In the current study target dosages were man-
ually fine-tuned during the manual post optimisation.
Krayenbuehl et al. showed in a retrospective study that Auto-
plan also can improve plan quality when compared to a different
treatment planning system, Eclipse. This suggests that the plan
quality improvement presented here is more generic and not solely
related to Pinnacle [11]. Krayenbuehl et al. did not use any post AU
optimisation, which explains the difference in planning time. They
only spent on average 4 min setting up the AU plan, where in the
current study the planning time included plan evaluation and
post-AU optimisation.
In the post optimisation process extra objectives were added if
violations of the guidelines for critical structures (spinal cord or
brain stem) or targets were observed. Even with the critical struc-
tures set to ‘‘none compromise” the max dose could exceed the tol-
erance slightly for patients with targets close to the OAR. This was
solved by adding a max dose objective with high weight for the
specific OAR in the post optimisation. For the targets a single uni-
form dose objective was added for the CTV1 target (high dose tar-
get). This was done to reduce the mean CTV1 dose to match the
prescription dose within ±1%, as recommended within the
DAHANCA guidelines. The ‘‘need” of an additional constraint on
the high dose volume seems related to the difference between dose
prescription as recommended by the ICRU and RTOG guidelines
[15]. The ICRU guideline aims for a median target dose close to
the prescribed dose and thereby allows the minimum dose
(defined as D98%) to be 95% of the prescribed dose., RTOG aims
for a minimum target dose (defined as D95%) equal to the pre-
scribed dose. Therefore, the RTOG prescription will always give a
higher mean and median dose than the ICRU prescription. Auto-
plan in Pinnacle seems to adhere mainly to the RTOG guidelines
which could be the cause for an additional post Autoplan optimisa-
tion constraint on the high dose volume needed.
Automatic treatment planning is typically based on one of two
approaches. One being the atlas based model, where a group of
representative plans is used as a base for a model. A new treatment
plan is then created by comparing targets and OAR anatomy with
the model and from there derived the DVH objectives. One exam-ple of this is the commercial RapidPlan used in the treatment plan-
ning system Eclipse [8,16]. The second approach is template based
automatic treatment planning, where the automatic plan algo-
rithm tries to drive the optimisation according to template origi-
nated from a protocol. Two such systems are the Erasmus-iCycle
from the Rotterdam group which works with TPS Monaco [10]
and the Autoplan from Pinnacle3 used in this study. Both
approaches seem to create better or at least as good plans as a
highly experienced dosimetrist. An additional benefit of the tem-
plate based systems is that knowledge-sharing between centres
is easier and more robust. A centre would be able to create plans
of the same quality as presented in this study by coping Table 2.
If their prescription doses or OAR dose limits are different they
would just need to be adjusted in the AU template.
For the atlas based systems the plans quality will depend heav-
ily on the quality of the plans in the atlas. With sparse resources at
most centres it can be difficult to allocate time to generate an atlas
of very high plan quality. Potentially the Autoplan generated plans
could be used as the atlas database improving plan quality across
different TPS.
One of the main benefits of AU plans is the general sparing of
OAR compared to the MA plans. For H&N cancer treatment there
has been a focus during the last years for deescalating the treat-
ment doses for HPV positive tumours [17,18]. This is desired
because the treatment dose could be lowered and hence the toxi-
city could be reduced and potentially improving the quality of life
for the patients. With Autoplan the dose reduction to the OAR is
around 10%, which is roughly the same dose reduction the HPV
positive de-escalation trials are aiming for. The benefit of the Auto-
plan, however, is for all H&N cancer patients and comes with no
higher risk of recurrences, since the target doses are maintained,
hence, AU can be perceived as ‘‘free of charge”.
Another benefit of AU planning is in the adaptive radiotherapy
setting. In this study replanning, during treatment, was necessary
for 3 out of the 30 patients. Autoplan was also used to create the
new plans; however they were not included in the analysis. The
plans showed similar sparing of OAR and were substantially
quicker to produce compared to conventional manual replans.
The AU plans achieve improved planned dose distributions,
compared to MA, by adding more MLC modulation which can be
observed by an average increase of 75 MU per plan in this study.
This propagates into a slightly lower pass rate measure on the
ArcCheck phantom, however all plans were clinically acceptable.
Comparison to other TPS (Monaco or Eclipse) the number of MU
used by Autoplan for head and neck is still low [19–21].
In Autoplan the prioritisation of OAR only has four levels (low,
medium, high, non-compromise), which for some specific patients
will be too low and therefore it can be difficult to find the
appropriate compromise between target and multiple OARs. The
automatic nature of Autoplan makes manual interaction time-
consuming and therefore, a generic template is of vital importance.5. Conclusion
In conclusion, the Autoplan-generated treatment plans were
selected in 29 of 30 cases for clinical treatment of head and neck
cancer when selected blindedly head-on with the standard manual
planning method. The target coverage was similar with maintained
treatment doses while average OAR mean doses were reduced
between 0.5 and 6.5 Gy. The manual time spent on planning was
reduced by a factor of two and the delivery of the AU plans was
of high clinical quality, though the pass rate was slightly lower
compared to MA plans. From these results, AU planning has now
been implemented as the clinical standard of head and neck treat-
ment in our centre.
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